The sBLA was based on efficacy and safety data from the KEYNOTE-A18 trial.
Your search for bevacizumab returned 127 results
The Agency could not approve the BLA due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
Lonsurf is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor.
Researchers say they have identified an unintended effect of Medicare’s 340B Drug Pricing Program; increases in spending for outpatient cancer treatments among patients with commercial insurance.
Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
The approval was based on data from the SORAYA trial.
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…